Clinical stage biotech company that focuses on the development and comercialization of autologous, allogeneic therapies.
NKGen Biotech, Inc. is a dynamic clinical-stage biotechnology firm specializing in the development and advancement of innovative natural killer (NK) cell therapies. Focused on both autologous and allogeneic approaches, as well as CAR-NK technologies, the company is committed to pioneering treatments that harness the natural capabilities of NK cells for therapeutic purposes.
Among its flagship products, SNK01 stands out as an autologous NK cell therapy designed to address neurodegenerative diseases. Additionally, SNK02, an allogeneic NK cell therapy, is currently undergoing Phase 1 clinical trials targeting refractory solid tumors, showcasing the company's diverse therapeutic applications and potential.
Established in 2017 and headquartered in Santa Ana, California, NKGen Biotech, Inc. originated as NKMAX America, Inc. before rebranding. Operating as a subsidiary of NKMAX Co., Ltd., the company benefits from synergies within the NKMAX network, leveraging shared expertise and resources to accelerate the development and commercialization of innovative NK cell therapies worldwide.